CY1106785T1 - Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο - Google Patents

Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο

Info

Publication number
CY1106785T1
CY1106785T1 CY20071101031T CY071101031T CY1106785T1 CY 1106785 T1 CY1106785 T1 CY 1106785T1 CY 20071101031 T CY20071101031 T CY 20071101031T CY 071101031 T CY071101031 T CY 071101031T CY 1106785 T1 CY1106785 T1 CY 1106785T1
Authority
CY
Cyprus
Prior art keywords
vaccine
human cytomegalovirus
virus particles
cytomegalovirus infection
particles released
Prior art date
Application number
CY20071101031T
Other languages
English (en)
Inventor
Bodo Plachter
Original Assignee
Bodo Plachter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodo Plachter filed Critical Bodo Plachter
Publication of CY1106785T1 publication Critical patent/CY1106785T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Αντικείμενο της εφεύρεσης είναι ιικά σωματίδια, τα οποία απελευθερώνονται από κύτταρα θηλαστικών μετά από μόλυνση από ανθρώπινο κυτταρομεγαλοϊό (ΗCMV), καθώς και σωματίδια των οποίων η αντιγονικότητα βελτιστοποιήθηκε μέσω γονιδιοτεχνολογικής μεταβολής του ΗCMV. Η εφεύρεση αναφέρεται επίσης στη χρήση τέτοιων σωματιδίων ως εμβόλιο, καθώς και σε μέθοδο για τον πολλαπλασιασμό του ΗCMV σε κύτταρα θηλαστικών.
CY20071101031T 1999-03-08 2007-08-02 Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο CY1106785T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910044A DE19910044A1 (de) 1999-03-08 1999-03-08 Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
PCT/EP2000/001794 WO2000053729A2 (de) 1999-03-08 2000-03-02 Virale partikel, die nach infektion durch humanes cytomegalovirus freigesetzt werden und ihre verwendung als impfstoff

Publications (1)

Publication Number Publication Date
CY1106785T1 true CY1106785T1 (el) 2012-05-23

Family

ID=7900043

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101031T CY1106785T1 (el) 1999-03-08 2007-08-02 Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο

Country Status (12)

Country Link
US (2) US6713070B1 (el)
EP (1) EP1159405B1 (el)
JP (1) JP4528447B2 (el)
AT (1) ATE365205T1 (el)
AU (1) AU767460B2 (el)
CA (1) CA2365903C (el)
CY (1) CY1106785T1 (el)
DE (2) DE19910044A1 (el)
DK (1) DK1159405T3 (el)
ES (1) ES2284486T3 (el)
PT (1) PT1159405E (el)
WO (1) WO2000053729A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004661A1 (en) * 2004-06-25 2006-01-12 Medimmune Vaccines, Inc. Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
CA2682700A1 (en) * 2007-05-11 2008-11-20 Vakzine Projekt Management Gmbh Composition containing hcmv particles
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
LT2556150T (lt) * 2010-04-06 2016-12-12 Vakzine Projekt Management Gmbh Išlaisvinama po žinduolio ląstelių užkrėtimo žmogaus citomegalovirusu (hcmv) virusinė dalelė, turinti sulietą baltymą, ir jos panaudojimas
TW201305190A (zh) * 2010-10-15 2013-02-01 Glaxosmithkline Biolog Sa 新穎之抗原
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
KR102301463B1 (ko) 2011-11-11 2021-09-14 배리에이션 바이오테크놀로지스 아이엔씨. 사이토메갈로바이러스의 치료를 위한 조성물 및 방법
CN104321444A (zh) 2012-03-27 2015-01-28 变异生物技术公司 用于检测抗巨细胞病毒中和抗体的方法
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
WO2014060594A1 (en) * 2012-10-19 2014-04-24 Cevec Pharmaceuticals Gmbh Production of a hcmv based vaccine in human amniocyte cell lines
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
JP7449246B2 (ja) 2018-06-08 2024-03-13 ワクチン プロジェクト マネジメント ゲーエムベーハー ウイルス粒子ベースのワクチン
EP3587566A1 (en) 2018-06-29 2020-01-01 Bodo Plachter Hcmv vaccine strain
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE118822T1 (de) * 1987-06-26 1995-03-15 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
CA2068066C (en) * 1991-05-07 2005-11-22 Charles Cunningham Herpesvirus particles and vaccine
DE4426453C1 (de) * 1994-07-26 1995-11-02 Biotest Ag Rekombinant hergestellte Fusionsproteine des Cytomegalievirus und diese enthaltende diagnostische Testkits
DE19619255A1 (de) * 1995-05-17 1996-11-28 Hartmut Prof Dr Link Hexadekameres Peptid, Vakzine, Herstellungsverfahren und Verwendung
US5830727A (en) * 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5800981A (en) * 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Also Published As

Publication number Publication date
EP1159405A2 (de) 2001-12-05
US20040152182A1 (en) 2004-08-05
JP2002537830A (ja) 2002-11-12
EP1159405B1 (de) 2007-06-20
AU767460B2 (en) 2003-11-13
CA2365903C (en) 2013-02-12
PT1159405E (pt) 2007-07-30
DE19910044A1 (de) 2000-09-14
ATE365205T1 (de) 2007-07-15
DE50014426D1 (de) 2007-08-02
CA2365903A1 (en) 2000-09-14
AU3808200A (en) 2000-09-28
JP4528447B2 (ja) 2010-08-18
WO2000053729A2 (de) 2000-09-14
ES2284486T3 (es) 2007-11-16
WO2000053729A3 (de) 2000-12-28
DK1159405T3 (da) 2007-10-01
US6713070B1 (en) 2004-03-30

Similar Documents

Publication Publication Date Title
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
DE60033284D1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HUP9903829A1 (hu) RNS-vírusok fertőző klónjai,belőlük kifejlesztett vakcinák és diagnosztikai eljárások
HK1062029A1 (en) Multiplication of viruses in a cell culture
CY1113689T1 (el) Εξασθενημενοι ιοι αρνητικου κλωνου με αλλοιωμενη δραστικοτητα ανταγωνισμου ιντερφερονης για χρηση ως εμβολια και φαρμακευτικα προϊοντα
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
CY1118138T1 (el) Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
DE60330795D1 (de) Impfstoff gegen west nile virus
ATE368116T1 (de) Schutzantigen des epstein-barr-virus
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
EP0247873A3 (en) Bacteriocins and compositions thereof in anti-viral treatment
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
WO2002089728A3 (en) Recombinant rhabdoviruses as live-viral vaccines
SE0002498D0 (sv) Papillomavirus vaccine
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas